Integrative review of managed entry agreements: chances and limitations


10 October 2020 - Managed entry agreements consist of a set of instruments to reduce the uncertainty and the budget impact of new high-priced medicines; however, there are concerns. 

There is a need to critically appraise managed entry agreements with their planned introduction in Brazil. 

Accordingly, the objective of this article is to identify and appraise key attributes and concerns with MEAs among payers and their advisers, with the findings providing critical considerations for Brazil and other high- and middle-income countries.

Read PhamacoEconomics article

Michael Wonder

Posted by:

Michael Wonder